Edition:
India

Exelixis Announces U.S. FDA Approval Of Cabometyx Tablets For Previously Treated Hepatocellular Carcinoma


Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA.EXELIXIS INC - APPROVAL BASED ON CELESTIAL PHASE 3 PIVOTAL TRIAL. 

Company Quote

16.42
-0.58 -3.41%
18 Oct 2019